ciglitazone has been researched along with clofibrate in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (6.67) | 18.7374 |
1990's | 1 (6.67) | 18.2507 |
2000's | 8 (53.33) | 29.6817 |
2010's | 5 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aizawa, Y; Fujita, T; Hasegawa, K; Horikoshi, H; Kanai, T; Kurumada, T; Yoshioka, T | 1 |
Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Baik, EJ; Kim, EJ; Kwon, KJ; Lee, SH; Moon, CH; Park, JY | 1 |
Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS | 1 |
Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T | 1 |
Beauregard, C; Brandt, PC | 1 |
Newaz, M; Oyekan, A; Yousefipour, Z | 1 |
Catalán, J; Giral, H; Sorribas, V; Villa-Bellosta, R | 1 |
Chang, S; Choi, EH; Demerjian, M; Elias, PM; Feingold, KR; Man, MQ | 1 |
Crowe, DL; Han, JS | 1 |
1 review(s) available for ciglitazone and clofibrate
Article | Year |
---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
14 other study(ies) available for ciglitazone and clofibrate
Article | Year |
---|---|
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
Topics: Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Male; Mice; Mice, Inbred BALB C; Phenols; Rats; Structure-Activity Relationship | 1989 |
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2.
Topics: Animals; Cell Culture Techniques; Cell Death; Chromans; Clofibrate; Cyclooxygenase 2; Dinoprostone; Electrophoretic Mobility Shift Assay; Escherichia coli; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Lipopolysaccharides; Mice; Mice, Inbred ICR; Neurons; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Peroxisome Proliferators; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells.
Topics: Animals; Cell Line, Transformed; Chromans; Clofibrate; Dexamethasone; Gene Expression; Humans; Interleukin-1; Lacrimal Apparatus; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; PPAR alpha; PPAR gamma; Pterins; Pyrimidines; Rabbits; Thiazolidinediones; Troglitazone | 2003 |
Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acute Kidney Injury; Angiotensin II; Animals; Ascorbic Acid; Clofibrate; Down-Regulation; Free Radicals; Glycerol; Kidney; Male; Nitric Oxide; Nitriles; PPAR gamma; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazolidinediones; Thromboxane A2; Vasoconstriction | 2006 |
Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines.
Topics: Animals; Caspase 3; Cell Line; Cell Survival; Clofibrate; DNA Fragmentation; Hypoglycemic Agents; Hypolipidemic Agents; Kidney Tubules, Proximal; L-Lactate Dehydrogenase; LLC-PK1 Cells; Mice; Opossums; Peroxisome Proliferators; Pioglitazone; PPAR alpha; PPAR gamma; Pyrimidines; Swine; Thiazolidinediones | 2007 |
Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Topics: Animals; Cell Differentiation; Cell Membrane Permeability; Cell Proliferation; Clobetasol; Clofibrate; DNA-Binding Proteins; Epidermis; Female; Glucocorticoids; Hydroxycholesterols; Keratinocytes; Liver X Receptors; Male; Mice; Mice, Hairless; Models, Animal; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones | 2009 |
Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatin Assembly and Disassembly; Clofibrate; CREB-Binding Protein; Fatty Acids, Unsaturated; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Invasiveness; Nuclear Receptor Coactivator 1; Peroxisome Proliferator-Activated Receptors; Promoter Regions, Genetic; Retinoid X Receptors; Tetrahydronaphthalenes; Thiazolidinediones; Time Factors; Transfection; Tumor Burden | 2010 |